top of page
Search

UK MHRA: Guidance on Operational Information Sharing

Writer's picture: Sharan MuruganSharan Murugan
Jan 2, 20241 min read

Earlier today (02 January 2024) UK's Medicines and Healthcare Products Regulatory Agency (MHRA) released updated guidance on "Operational Information Sharing" that provides detailed information for Marketing Authorisation (MA) applicants on providing consent to share operational information during the MA application process.


Operational information is defined as administrative information about an application.


To ensure the smooth functioning of the medicine approval process, the Medicines and Healthcare products Regulatory Agency ("MHRA") has developed a process to share operational information with health system partners across the UK. This procedure applies to medicines being approved under the National and International Recognition routes.


In order to minimize delays in patient access to newly authorised treatments, information sharing with health system partners is intended to facilitate the most efficient access to medical products. As soon as consent has been obtained from the proposed MAH, information will be shared with health system partners who have made appropriate commitments on how the data will be used and stored.


Some of the Health Partners who are expected to commit to the underpinning Operational Information Sharing arrangement to access the operational information shared:

  • The National Institute for Health and Care Excellence (NICE)

  • National Health Service England (NHSE)

  • All Wales Therapeutics and Toxicology Centre (AWTTC)

  • NHS Wales Shared Services Partnership (NWSSP) hosted by Velindre NHS Trust

  • Scottish Medicines Consortium (SMC) as part of Healthcare Improvement Scotland (HIS)

  • NHS National Services Scotland (NHS NSS)

  • Scottish Government

  • Welsh Government


For further information on How to provide consent, Information management, Consent and withdrawal click this LINK.




 
 
 

Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page